Swiss Biotech Revenue Reaches Record 7.5 Billion Francs
Revenue for the Swiss biotech sector reached a record 7.5 billion francs in 2025. Private funding rose 38 percent as firms favored research collaborations.
Xurve View
Xurve View
Switzerland biotech funding rose 2.1% to 2.6B francs ($3.32B) in 2025 as private investment surged 38% to offset tight capital markets. Private capital now accounts for nearly half of all sector funding, according to the Swiss Biotech Report 2026. Investors are pivoting toward R&D collaborations and licensing deals to de-risk structures in a challenging post-pandemic environment.
